Brief: Immunocore announces initial Phase 1 data of ImmTAC® candidate IMC-C103C targeting MAGE-A4

Immunocore Holdings

06/12/2021 12:59

Dec 6 (Reuters) - Immunocore Holdings PLC  IMCR.O :
    * IMMUNOCORE ANNOUNCES INITIAL PHASE 1 DATA OF IMMTAC®
CANDIDATE
IMC-C103C TARGETING MAGE-A4
    * IMMUNOCORE HOLDINGS PLC - CLINICAL ACTIVITY WITH CONFIRMED
DURABLE RESPONSES IN OVARIAN CANCER AND A CONFIRMED DURABLE
RESPONSE IN HNSCC
    * IMMUNOCORE HOLDINGS PLC - BIOMARKERS OF T CELL ACTIVATION
CONSISTENT AND ROBUST AT DOSES ≥ 90 MICROGRAMS
    * IMMUNOCORE HOLDINGS PLC - FIRST EXPANSION IN HIGH GRADE
SEROUS
OVARIAN CANCER INITIATED
    * IMMUNOCORE HOLDINGS PLC - IMC-C103C DEMONSTRATED A
MANAGEABLE
SAFETY PROFILE

Source text for Eikon:  ID:nGNXb4TMMM 
Further company coverage:  IMCR.O 

 ((Reuters.Briefs@thomsonreuters.com;;))